MCK - McKesson Corp Stock Price, Fair Value and News

528.48USD+5.80 (+1.11%)Market Closed

Market Summary

USD528.48+5.80

Market Closed

1.11%

MCK Alerts

1 major insider sales recently.

MCK Stock Price

View Fullscreen

MCK RSI Chart

MCK Valuation

Market Cap

70.0B

Price/Earnings (Trailing)

23.36

Price/Sales (Trailing)

0.23

EV/EBITDA

18.16

Price/Free Cashflow

22.41

MCK Price/Sales (Trailing)

MCK Profitability

Operating Margin

32.82%

EBT Margin

1.18%

Return on Equity

37.95%

Return on Assets

4.51%

Free Cashflow Yield

4.46%

MCK Fundamentals

MCK Revenue

Revenue (TTM)

301.5B

Rev. Growth (Yr)

14.77%

Rev. Growth (Qtr)

4.77%

MCK Earnings

Earnings (TTM)

3.0B

Earnings Growth (Yr)

-45.41%

Earnings Growth (Qtr)

-11.3%

Breaking Down MCK Revenue

Last 7 days

0.2%

Last 30 days

-1.0%

Last 90 days

8.8%

Trailing 12 Months

45.5%

How does MCK drawdown profile look like?

MCK Financial Health

Current Ratio

0.92

Debt/Equity

0.71

Debt/Cashflow

0.62

MCK Investor Care

Dividend Yield

0.42%

Buy Backs (1Y)

5.29%

Diluted EPS (TTM)

22.07

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2023	276.7B	284.0B	291.1B	301.5B
2022	264.0B	268.4B	272.0B	273.9B
2021	238.2B	245.2B	251.0B	257.0B
2020	231.1B	231.0B	234.2B	237.6B
2019	214.3B	217.4B	222.0B	224.9B
2018	208.4B	209.9B	210.9B	213.5B
2017	198.5B	199.9B	202.0B	205.4B
2016	190.9B	193.1B	194.3B	196.5B
2015	179.0B	183.1B	187.7B	189.1B
2014	137.4B	148.6B	159.8B	172.0B
2013	122.1B	123.6B	126.8B	130.1B
2012	122.7B	123.5B	123.0B	123.3B
2011	112.1B	114.6B	117.3B	119.9B
2010	108.7B	109.5B	109.9B	109.9B
2009	106.6B	106.6B	107.1B	108.3B
2008	101.7B	102.9B	104.2B	105.4B

Get all data in R, Python etc through our Historical Stock Data APIs

GRUFITY'S FAIR VALUE MODEL

Stocks Marked 'Very Cheap' by Grufity's Fair Value Model Have Outperformed S&P 500 Index

Grufity's Fair Value model takes all the S&P 500 stocks and divides them into separate buckets based on their attractiveness. The 'Very Cheap' bucket of S&P 500 has greatly outperformed S&P 500 Index. Conversely, S&P500 stocks considered 'Very Expensive' by the model underperformed the S&P500 index in the past three years. Grufity Fair Value is available for 2300+ stocks, including 90% of S&P 500 stocks. Grufity's Fair Value Model separates high-return stocks from low-return stocks.

Returns of $10,000 invested in:

Very Cheap Stocks: $17,289
S&P 500 Index: $12,922
Very Expensive Stocks: $11,022

Grufity's Fair Value model does a great job in separating High Performing Stocks from Low Performing ones in the S&P 500 list.

S&P 500 Index

Very Expensive Stocks

Very Cheap Stocks

Try For Just $1.99

Tracking the Latest Insider Buys and Sells of McKesson Corp

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Mar 15, 2024	tyler brian s.	sold	-1,821,760	524	-3,473	chief executive officer
Mar 15, 2024	tyler brian s.	acquired	552,207	159	3,473	chief executive officer
Mar 04, 2024	rutledge napoleon b jr	sold	-100,698	529	-190	svp, controller & cao
Mar 01, 2024	rutledge napoleon b jr	sold (taxes)	-128,315	525	-244	svp, controller & cao
Mar 01, 2024	rutledge napoleon b jr	acquired	-	-	785	svp, controller & cao
Feb 13, 2024	smith leann b	sold	-92,256	496	-186	evp & chief hr officer
Feb 10, 2024	smith leann b	sold (taxes)	-67,682	501	-135	evp & chief hr officer
Feb 10, 2024	smith leann b	acquired	-	-	507	evp & chief hr officer
Jan 03, 2024	tyler brian s.	acquired	1,945,900	138	14,026	chief executive officer
Jan 03, 2024	tyler brian s.	sold	-6,732,480	480	-14,026	chief executive officer

Which funds bought or sold MCK recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
Apr 15, 2024	ERn Financial, LLC	new	-	213,129	213,129	0.04%
Apr 15, 2024	WEALTH ENHANCEMENT ADVISORY SERVICES, LLC	reduced	-4.36	9,602,100	97,716,500	0.25%
Apr 15, 2024	Sound Income Strategies, LLC	unchanged	-	1,477	10,737	-%
Apr 15, 2024	One Wealth Advisors, LLC	added	121	745,930	1,221,140	0.21%
Apr 15, 2024	ATLAS CAPITAL ADVISORS LLC	reduced	-2.22	364,693	3,091,180	0.48%
Apr 15, 2024	RMR Wealth Builders	added	5.22	44,968	249,123	0.03%
Apr 15, 2024	THOMPSON INVESTMENT MANAGEMENT, INC.	reduced	-2.8	709,639	6,294,570	0.95%
Apr 15, 2024	Alhambra Investment Management LLC	new	-	220,645	220,645	0.12%
Apr 15, 2024	Mosley Wealth Management	reduced	-3.66	32,585	310,836	0.29%
Apr 15, 2024	TruWealth Advisors, LLC	new	-	228,711	228,711	0.02%

Are Funds Buying or Selling MCK?

Are funds buying MCK calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own MCK

No. of Funds

MCK Alerts

1 major insider sales recently.

Unveiling McKesson Corp's Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Feb 13, 2024	vanguard group inc	9.13%	12,145,675	SC 13G/A
Jan 25, 2024	blackrock inc.	8.8%	11,665,986	SC 13G/A
Feb 09, 2023	vanguard group inc	9.08%	12,869,151	SC 13G/A
Feb 03, 2023	blackrock inc.	8.3%	11,784,945	SC 13G/A
Feb 10, 2022	vanguard group inc	10.15%	15,497,451	SC 13G/A
Feb 01, 2022	blackrock inc.	8.6%	13,171,252	SC 13G/A
Feb 16, 2021	capital ventures international	0.5%	865,164	SC 13G/A
Feb 10, 2021	vanguard group inc	10.12%	16,251,909	SC 13G/A
Jan 29, 2021	blackrock inc.	8.7%	13,969,975	SC 13G/A
Oct 13, 2020	vanguard group inc	10.17%	16,496,553	SC 13G/A

Recent SEC filings of McKesson Corp

View All Filings

Date Filed	Form Type	Document
Mar 18, 2024	4	Insider Trading
Mar 15, 2024	144	Notice of Insider Sale Intent
Mar 05, 2024	4	Insider Trading
Feb 14, 2024	4	Insider Trading
Feb 13, 2024	SC 13G/A	Major Ownership Report
Feb 13, 2024	144	Notice of Insider Sale Intent
Feb 12, 2024	4	Insider Trading
Feb 12, 2024	4	Insider Trading
Feb 12, 2024	4	Insider Trading
Feb 08, 2024	10-Q	Quarterly Report

Peers (Alternatives to McKesson Corp)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
ABT	189.6B	40.1B	-5.40%	4.53%	33.12	4.73	-8.12%	-17.45%
BDX	66.7B	19.5B	-2.42%	-9.87%	53.13	3.42	4.02%	-22.04%
ALGN	22.9B	3.9B	-2.94%	-12.25%	51.49	5.93	3.42%	23.09%
BAX	20.1B	14.8B	-4.93%	-7.94%	7.56	1.36	2.12%	209.17%
MID-CAP
HSIC	9.2B	12.3B	-4.49%	-14.03%	22	0.74	-2.44%	-22.68%
ATR	9.2B	3.5B	-1.69%	15.70%	32.17	2.62	4.97%	18.89%
BIO	8.5B	2.7B	-12.27%	-39.23%	-13.41	3.2	-4.68%	82.43%
XRAY	6.4B	4.0B	-6.21%	-24.72%	-47.49	1.61	1.10%	85.84%
AXNX	3.4B	366.4M	-0.75%	15.36%	-565.58	9.37	33.86%	89.83%
PDCO	2.3B	6.6B	-5.91%	-4.69%	11.86	0.35	2.78%	-0.87%
SMALL-CAP
AHCO	1.3B	3.2B	-6.61%	-18.37%	-1.88	0.4	7.73%	-1066.14%
ANIK	380.0M	166.7M	0.59%	-11.05%	-4.6	2.28	6.67%	-456.34%
ANGO	260.4M	324.0M	21.04%	-28.41%	-1.35	0.8	-3.19%	-337.41%
APYX	48.2M	52.3M	-22.35%	-53.67%	-2.57	0.92	17.61%	19.28%
AEMD	3.8M	3.7M	-16.76%	269.23%	-0.31	1.01	5.77%	8.23%

McKesson Corp News

Latest updates

McKesson Corp Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Income Statement (Quarterly)																					(In Millions)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4
Revenue	4.8%	80,898	77,215	74,483	68,910	70,490	70,157	67,154	66,102	68,614	66,576	62,674	59,142	62,599	60,808	55,679	58,535	59,172	57,616	55,728	52,429	56,208
Gross Profit	2.7%	3,152	3,069	3,022	3,066	3,174	3,095	3,023	3,318	3,428	3,352	3,032	3,297	3,151	3,000	2,700	3,336	3,033	2,867	2,787	3,201	2,970
Operating Expenses	18.5%	2,510	2,118	1,922	2,086	1,933	1,971	1,987	2,685	3,130	2,813	2,464	2,287	10,513	2,366	2,022	2,467	2,673	2,241	2,153	3,770	2,287
S&GA Expenses	19.8%	2,506	2,092	1,870	1,964	1,903	1,950	1,959	2,531	3,105	2,669	2,232	2,224	2,291	2,237	2,097	-	-	-	-	-	-
EBITDA Margin	-20.0%	0.01*	0.02*	0.02*	0.02*	0.02*	0.01*	0.01*	0.01*	0.01*	-0.02*	-0.02*	-0.02*	-0.02*	0.01*	0.01*	0.01*	-	-	-	-	-
Interest Expenses	4.9%	64.00	61.00	47.00	79.00	69.00	55.00	45.00	43.00	41.00	45.00	49.00	52.00	55.00	50.00	-	-	-	-	-	-	-
Income Taxes	-108.5%	-18.00	213	94.00	106	329	271	199	240	238	132	26.00	316	-1,200	28.00	150	129	47.00	-294	136	111	123
Earnings Before Taxes	-33.2%	612	916	1,091	932	1,448	1,244	1,006	647	277	442	562	1,029	-7,363	655	645	1,201	294	-970	619	-633	650
EBT Margin	-21.8%	0.01*	0.02*	0.02*	0.02*	0.02*	0.01*	0.01*	0.01*	0.01*	-0.02*	-0.02*	-0.02*	-0.02*	0.01*	0.01*	0.00*	-	-	-	-	-
Net Income	-11.3%	589	664	958	787	1,079	926	768	368	-7.00	267	486	666	-6,226	577	444	1,021	186	-730	423	-796	469
Net Income Margin	-17.0%	0.01*	0.01*	0.01*	0.01*	0.01*	0.01*	0.01*	0.00*	0.01*	-0.02*	-0.02*	-0.02*	-0.02*	0.01*	0.00*	0.00*	-	-	-	-	-
Free Cashflow	-81.6%	164	890	-1,130	3,200	1,560	1,021	-1,012	2,752	1,310	1,699	-1,715	3,212	1,094	919	-1,134	4,534	-	-	-	-	-

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet																					(In Millions)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4
Assets	0.6%	66,512	66,091	64,096	62,320	62,690	63,081	62,295	63,298	63,708	63,601	62,894	65,015	61,845	61,558	57,666	61,247	60,873	58,994	61,680	59,672	61,011
Current Assets	0.2%	47,640	47,531	45,539	44,292	44,657	46,448	45,383	46,231	46,498	45,580	43,350	45,382	42,368	42,345	38,682	42,222	39,390	37,353	38,428	38,465	38,319
Cash Equivalents	-21.5%	1,982	2,524	2,636	4,678	2,774	2,916	2,233	3,935	2,754	2,151	2,423	6,278	3,577	3,091	2,613	4,023	2,065	1,356	1,947	2,981	1,849
Inventory	0.3%	22,020	21,945	20,510	19,691	20,657	19,876	19,505	18,702	19,024	19,342	20,016	19,200	19,211	18,435	16,607	16,734	17,020	16,356	16,604	16,709	16,951
Net PPE	1.4%	2,201	2,171	2,172	2,177	2,140	2,071	2,083	2,092	2,064	2,222	2,549	2,581	2,518	2,471	2,392	2,365	2,408	2,493	2,466	2,548	2,503
Goodwill	0.4%	9,973	9,934	9,971	9,947	9,934	9,239	9,368	9,451	9,462	9,473	9,520	9,493	9,511	9,414	9,419	9,360	9,456	9,408	388	9,358	386
Current Liabilities	1.0%	51,661	51,147	48,422	47,957	48,006	48,357	47,201	48,466	47,452	46,075	43,835	44,103	41,930	42,724	38,600	42,624	40,055	37,145	37,952	37,626	37,424
Short Term Borrowings	-	218	-	-	-	617	-	-	-	372	-	-	-	152	-	-	-	2,109	549	-	-	1,048
Long Term Debt	1.6%	5,625	5,535	5,611	4,626	5,452	4,813	4,976	5,080	5,518	5,946	6,424	6,406	6,467	5,848	6,395	6,335	6,734	7,342	7,382	7,265	7,616
LT Debt, Current	-	-	-	-	-	-	-	-	-	-	-	-	-	-	1,760	1,053	1,052	1,007	302	310	330	1,120
LT Debt, Non Current	-	-	-	-	-	-	-	-	-	5,518	5,946	-	6,406	-	5,848	6,395	6,335	6,734	7,342	7,382	7,265	7,616
Shareholder's Equity	-	-	-	-	-	-	-	-	-	-	-	-	175	-	6,090	5,653	5,309	6,385	6,692	8,068	8,287	9,389
Retained Earnings	3.7%	14,268	13,761	13,182	12,295	11,582	10,579	9,732	9,030	8,734	8,812	8,618	8,202	7,595	13,890	13,384	13,022	12,075	11,965	12,770	12,409	13,276
Additional Paid-In Capital	0.8%	7,962	7,899	7,824	7,747	7,536	7,609	7,350	7,275	7,411	7,311	7,057	6,925	6,847	6,780	6,711	6,663	6,614	6,573	6,483	6,435	6,321
Shares Outstanding	-1.2%	133	134	136	141	140	144	144	152	152	155	156	161	160	162	162	181	179	183	188	-	-
Minority Interest	1.9%	371	364	362	367	366	518	532	480	487	484	484	196	200	200	207	217	211	210	194	193	204
Float	-	-	-	-	-	-	48,200	-	-	-	30,400	-	-	-	23,900	-	-	-	25,000	-	-	-

Cashflow (Last 12 Months)

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Cashflow (Quarterly)																					(In Millions)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4
Cashflow From Operations	-73.7%	254	965	-1,052	3,325	1,668	1,107	-941	2,887	1,377	1,792	-1,622	3,370	1,213	1,021	-1,062	4,654	-121	-108	-51.00	3,895	-177
Cashflow From Investing	-8.4%	-180	-166	-149	-244	-414	77.00	39.00	183	-115	-58.00	-99.00	-205	68.00	-148	-130	-170	-124	-156	-129	-230	-168
Cashflow From Financing	31.6%	-622	-909	-843	-1,190	-1,425	-572	-1,181	-1,989	-438	-1,743	-2,151	-517	-775	-462	61.00	-2,480	949	-331	-872	-2,544	119
Dividend Payments	10.7%	83.00	75.00	74.00	76.00	77.00	68.00	71.00	71.00	72.00	65.00	69.00	67.00	69.00	66.00	74.00	72.00	74.00	73.00	75.00	76.00	77.00
Buy Backs	3.3%	868	840	696	138	1,976	524	1,000	1,515	728	280	1,008	242	231	269	-	-17.00	500	750	701	252	500

MCK Income Statement

2023-12-31

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($) shares in Millions, $ in Millions	3 Months Ended		9 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2023	Dec. 31, 2022
Income Statement [Abstract]
Revenues	$ 80,898	$ 70,490	$ 232,596	$ 207,801
Cost of sales	(77,746)	(67,316)	(223,353)	(198,509)
Gross profit	3,152	3,174	9,243	9,292
Selling, distribution, general, and administrative expenses	(2,506)	(1,903)	(6,468)	(5,812)
Claims and litigation charges, net	0	1	2	5
Restructuring, impairment, and related charges, net	(4)	(31)	(84)	(84)
Total operating expenses	(2,510)	(1,933)	(6,550)	(5,891)
Operating income	642	1,241	2,693	3,401
Other income, net	34	276	98	466
Interest expense	(64)	(69)	(172)	(169)
Income from continuing operations before income taxes	612	1,448	2,619	3,698
Income tax benefit (expense)	18	(329)	(289)	(799)
Income from continuing operations	630	1,119	2,330	2,899
Income (loss) from discontinued operations, net of tax	0	1	0	(3)
Net income	630	1,120	2,330	2,896
Net income attributable to noncontrolling interests	(41)	(41)	(119)	(123)
Net income attributable to McKesson Corporation	$ 589	$ 1,079	$ 2,211	$ 2,773
Diluted
Continuing operations (in usd per share)	$ 4.42	$ 7.65	$ 16.39	$ 19.32
Discontinued operations (in usd per share)	0	0.01	0	(0.02)
Total (in dollars per share)	4.42	7.66	16.39	19.30
Basic
Continuing operations (in usd per share)	4.45	7.70	16.49	19.48
Discontinued operations (in usd per share)	0	0.01	0	(0.02)
Total (in dollars per share)	$ 4.45	$ 7.71	$ 16.49	$ 19.46
Weighted-average common shares outstanding
Diluted (in usd per share)	133.3	141.0	134.9	143.7
Basic (in shares)	132.5	139.9	134.0	142.5

MCK Balance Sheet

2023-12-31

CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($) $ in Millions	Dec. 31, 2023	Mar. 31, 2023
Current assets
Cash and cash equivalents	$ 1,982	$ 4,678
Receivables, net	23,066	19,410
Inventories, net	22,020	19,691
Prepaid expenses and other	572	513
Total current assets	47,640	44,292
Property, plant, and equipment, net	2,201	2,177
Operating lease right-of-use assets	1,679	1,635
Goodwill	9,973	9,947
Intangible assets, net	2,097	2,277
Other non-current assets	2,922	1,992
Total assets	66,512	62,320
Current liabilities
Drafts and accounts payable	46,699	42,490
Short-term borrowings	218	0
Current portion of long-term debt	48	968
Current portion of operating lease liabilities	296	299
Other accrued liabilities	4,400	4,200
Total current liabilities	51,661	47,957
Long-term debt	5,625	4,626
Long-term deferred tax liabilities	978	1,387
Long-term operating lease liabilities	1,421	1,402
Long-term litigation liabilities	6,128	6,625
Other non-current liabilities	2,381	1,813
McKesson Corporation stockholders’ deficit
Preferred stock, $0.01 par value, 100 shares authorized, no shares issued or outstanding	0	0
Common stock, $0.01 par value, 800 shares authorized, 278 and 277 shares issued at December 31, 2023 and March 31, 2023, respectively	3	3
Additional paid-in capital	7,962	7,747
Retained earnings	14,268	12,295
Accumulated other comprehensive loss	(812)	(905)
Treasury shares, at cost, 147 and 141 shares at December 31, 2023 and March 31, 2023, respectively	(23,474)	(20,997)
Total McKesson Corporation stockholders’ deficit	(2,053)	(1,857)
Noncontrolling interests	371	367
Total deficit	(1,682)	(1,490)
Total liabilities and deficit	$ 66,512	$ 62,320

About McKesson Corp

McKesson Corporation provides healthcare services in the United States and internationally. It operates through four segments: U.S. Pharmaceutical, Prescription Technology Solutions (RxTS), Medical-Surgical Solutions, and International. The U.S. Pharmaceutical segment distributes branded, generic, specialty, biosimilar and over-the-counter pharmaceutical drugs, and other healthcare-related products. This segment also provides practice management, technology, clinical support, and business solutions to community-based oncology and other specialty practices; and consulting, outsourcing, technological, and other services, as well as sells financial, operational, and clinical solutions to pharmacies. The RxTS segment serves biopharma and life sciences partners and patients to address medication challenges for patients by working across healthcare; connects patients, pharmacies, providers, pharmacy benefit managers, health plans, and biopharma companies to deliver innovative solutions to help people get the medicine needed to live healthier lives; and provides prescription price transparency, benefit insight, dispensing support, third-party logistics, and wholesale distribution support services. The Medical-Surgical Solutions segment provides medical-surgical supply distribution, logistics, and other services to healthcare providers, including physician offices, surgery centers, nursing homes, hospital reference labs, and home health care agencies. The International segment offers distribution and services to wholesale, institutional, and retail customers in Europe and Canada. McKesson Corporation was founded in 1833 and is headquartered in Irving, Texas.

CEO	Mr. Brian S. Tyler Ph.D.
WEBSITE	mckesson.com
INDUSTRY	Medical Instruments & Supplies
EMPLOYEES	45000

McKesson Corp Frequently Asked Questions

What is the ticker symbol for McKesson Corp? What does MCK stand for in stocks?

MCK is the stock ticker symbol of McKesson Corp. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of McKesson Corp (MCK)?

As of Tue Apr 16 2024, market cap of McKesson Corp is 70.02 Billion. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of MCK stock?

You can check MCK's fair value in chart for subscribers.

What is the fair value of MCK stock?

You can check MCK's fair value in chart for subscribers. The fair value of McKesson Corp is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of McKesson Corp is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for MCK so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is McKesson Corp a good stock to buy?

The fair value guage provides a quick view whether MCK is over valued or under valued. Whether McKesson Corp is cheap or expensive depends on the assumptions which impact McKesson Corp's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for MCK.

What is McKesson Corp's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Tue Apr 16 2024, MCK's PE ratio (Price to Earnings) is 23.36 and Price to Sales (PS) ratio is 0.23. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. MCK PE ratio will change depending on the future growth rate expectations of investors.

What is 5 year return on McKesson Corp's stock?

In the past 10 years, McKesson Corp has provided 0.127 (multiply by 100 for percentage) rate of return.